




# Supplemental Figure 1. Immunophenotyping of NK cell stages and functional evaluation.



**Supplemental Figure 2. AHR agonists activate miR-29b promoter.**




**Supplemental Figure 3. Targets of miR-29b are downregulated following Stage 3 NK cell treatment with AML-derived conditioned media.**



# Supplemental Figure 4. NK cell numbers and function are altered by the presence of AML cells.

**A.**



**B.**

